Women Doctors' Network Calls for Gender-Specific Medical Research on International Women's Day - Why Medical Research Must Finally Prioritize Women's Unique Biology

A network of female physicians has called for major changes in medical research and healthcare. For decades, many approved drugs were tested mostly on men, leaving women at higher risk of adverse effects. The group argues that sex-specific differences must now shape how studies are designed and treatments prescribed.

Historically, women were often excluded from clinical trials, leading to gaps in drug safety and effectiveness. Even when included, their data was rarely analysed separately. This oversight has resulted in women experiencing more side effects, as medications were optimised for male biology.

Over the last ten years, progress has been made. Policies like the US FDA's 2014 action plan and EU guidelines now require sex-disaggregated data. Women's participation in Phase III trials has risen from around 40% to over 50%. Studies have uncovered key differences, such as slower metabolism of drugs like zolpidem in women, prompting label updates in 2021. Research also shows men often respond better to cardiovascular medications, while women may need adjusted dosages.

Initiatives like the 2022 NIH Sex as a Biological Variable programme have pushed for broader inclusion. Meta-analyses in journals such as Nature Reviews Drug Discovery highlight persistent underrepresentation in preclinical models. The physicians' network stresses that women's health extends beyond reproduction, affecting all organ systems. Biological, social, and gender-specific risks must now be embedded in research, guidelines, and healthcare systems.

While political interest in women's health is growing, the group insists more action is needed. They reject the outdated assumption that women are simply smaller versions of men. Differences in drug absorption, efficacy, and side effects demand tailored approaches.

The push for sex-specific medical research reflects a shift toward more precise and safer treatments. Updated guidelines and increased female participation in trials aim to reduce health disparities. However, full integration of these changes into clinical practice will require sustained effort and systemic reform.